「177Lu」Lu-NeoB治疗的安全性:一项表征吸收剂量与急性、早期和晚期器官毒性的临床前研究
该临床前研究在健康雌雄小鼠中重复给予「177Lu」Lu-NeoB,评估吸收剂量与急性、早期和晚期器官毒性;结果显示治疗总体可耐受,最显著的放射毒性见于肾脏,表现为肾积水和肾病并伴血尿素氮升高。
要点
- 「177Lu」Lu-NeoB重复给药总体可耐受,主要放射毒性靶器官为肾脏。
- 治疗组2和治疗组3在早期和晚期时间点出现肾积水和肾病,并伴血尿素氮升高。
- 胰腺和肝脏虽吸收剂量高,但未见明确显微镜下毒性征象。
核心结论
- 总体而言,重复给予「177Lu」Lu-NeoB可耐受,最显著的放射毒性见于肾脏,与其他临床应用的放射性配体相似。
- 本研究结果强调「177Lu」Lu-NeoB有潜力成为有前景的临床治疗选择。
研究设计与样本
- 健康雌性和雄性小鼠接受3次注射、间隔7天:对照组1给予溶媒,对照组2给予1200 pmol「175Lu」Lu-NeoB,治疗组1、2、3分别给予40 MBq/400 pmol、80 MBq/800 pmol、120 MBq/1200 pmol「177Lu」Lu-NeoB。
- 于首次注射后第5周、第19周和第43周分别评估急性、早期和晚期器官毒性,方法为组织病理学和血液分析。
- 同时进行广泛的生物分布和剂量学研究,以将观察到的毒性与吸收剂量相关联。
主要发现
- 生物分布研究显示吸收剂量最高见于表达GRPR的胰腺、肝脏和肾脏(主要排泄器官)。
- 两个对照组和治疗组1的几乎所有动物均未显示任何治疗相关毒理学效应。
- 尽管吸收剂量高,胰腺和肝脏未见明确的显微镜下毒性征象。
- 在早期和晚期时间点处死的治疗组2和治疗组3中,组织学分析显示肾积水和肾病形式的肾脏损伤,且同组动物血尿素氮水平升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The radiolabeled gastrin-releasing peptide receptor (GRPR)-targeting antagonist NeoB is a promising radioligand for imaging and therapy of GRPR-expressing malignancies. In the current study, we aimed to discover the target organs of toxicity and the radiotoxic effects to these organs, when repeated dosages of [177Lu]Lu-NeoB are administered to healthy female and male mice. METHODS: Animals received either 3 injections, with a 7-day interval, of vehicle (control group 1), 1200 pmol [175Lu]Lu-NeoB (control group 2) or 40 MBq/400 pmol, 80 MBq/800 pmol, and 120 MBq/1200 pmol [177Lu]Lu-NeoB (treatment groups 1, 2, and 3, respectively). At week 5, 19, and 43 after the first injection acute, early, and late organ toxicity, respectively, was determined. For this, histopathological and blood analyses were performed. To correlate the observed toxicity to absorbed dose, we also performed extensive biodistribution and dosimetry studies. RESULTS: The biodistribution study showed the highest absorbed doses in GRPR-expressing pancreas, the liver, and the kidneys (the main organs of excretion). Both control groups and almost all animals of treatment group 1 did not show any treatment-related toxicological effects. Despite the high absorbed doses, no clear microscopic signs of toxicity were found in the pancreas and the liver. Histological analysis indicated kidney damage in the form of hydronephrosis and nephropathy in treatment groups 2 and 3 that were sacrificed at the early and late time point. In the same groups, increased blood urea nitrogen levels were found. CONCLUSION: In general, repeated administration of [177Lu]Lu-NeoB was tolerated. The most significant radiotoxic effects were found in the kidneys, similar to other clinically applied radioligands. The results of this study underline the potential of [177Lu]Lu-NeoB as a promising option for clinical therapy.
引用
- Ruigrok EAM, Verhoeven M, Konijnenberg MW, et al. Safety of [177Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity. Eur J Nucl Med Mol Imaging. 2022. PMID: 35951084. doi:10.1007/s00259-022-05926-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。